ES2074513T3 - Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo. - Google Patents

Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo.

Info

Publication number
ES2074513T3
ES2074513T3 ES90122076T ES90122076T ES2074513T3 ES 2074513 T3 ES2074513 T3 ES 2074513T3 ES 90122076 T ES90122076 T ES 90122076T ES 90122076 T ES90122076 T ES 90122076T ES 2074513 T3 ES2074513 T3 ES 2074513T3
Authority
ES
Spain
Prior art keywords
antagonist
preparation
pharmaceutical composition
opiaceous
transdermic administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90122076T
Other languages
English (en)
Inventor
John David Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alko Oy AB
Original Assignee
Alko Oy AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Oy AB filed Critical Alko Oy AB
Application granted granted Critical
Publication of ES2074513T3 publication Critical patent/ES2074513T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

UTILIZACION DE UN ANTAGONISTA DE UN NARCOTICO PARA LA PREPARACION DE UN COMPUESTO FARMACEUTICO QUE SE ADMINISTRA TRANSDERMICAMENTE SIMULTANEAMENTE O SEPARADAMENTE CON ALCOHOL CONSECUTIVAMENTE Y MECANISMO PARA ADMINISTRAR TRANSDERMICAMENTE EL ANTAGONISTA. EL MECANISMO ES UN CONJUNTO QUE CONTIENE UNA DOSIS FIJA DE ANTOGONISTA DE UN NARCOTICO, UN VEHICULO Y UN ENFATIZADOR DE LA PERMEACION.
ES90122076T 1989-11-20 1990-11-19 Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo. Expired - Lifetime ES2074513T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/439,050 US5096715A (en) 1989-11-20 1989-11-20 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Publications (1)

Publication Number Publication Date
ES2074513T3 true ES2074513T3 (es) 1995-09-16

Family

ID=23743078

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90122076T Expired - Lifetime ES2074513T3 (es) 1989-11-20 1990-11-19 Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo.

Country Status (10)

Country Link
US (1) US5096715A (es)
EP (1) EP0429039B1 (es)
AT (1) ATE119393T1 (es)
AU (1) AU639042B2 (es)
CA (1) CA2030237C (es)
DE (1) DE69017596T2 (es)
DK (1) DK0429039T3 (es)
ES (1) ES2074513T3 (es)
FI (1) FI905718A (es)
NZ (2) NZ247173A (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
DE4223004A1 (de) * 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
PL341309A1 (en) 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
PL193273B1 (pl) 1997-12-22 2007-01-31 Euro Celtique Sa Postać dawkowania doustnego
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ATE399565T1 (de) * 1998-07-07 2008-07-15 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht- irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CN1423559A (zh) 2000-02-08 2003-06-11 欧罗赛铁克股份有限公司 包含阿片样激动剂和拮抗剂的控释组合物
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US20060121103A1 (en) * 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US7879211B2 (en) * 2001-07-13 2011-02-01 Arkray, Inc. Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
US7943173B2 (en) * 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
CA2478523A1 (en) 2002-04-05 2003-10-16 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
EP2422772A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7910599B2 (en) 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
HUE032156T2 (en) * 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2259780A2 (en) 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
SI2317991T1 (sl) * 2008-07-07 2017-09-29 Euro-Celtique S.A. Uporaba opioidnih antagonistov za zdravljenje retencije urina
ES2706407T3 (es) 2009-03-10 2019-03-28 Euro Celtique Sa Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11607026B2 (en) * 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
CN111447927A (zh) * 2017-12-08 2020-07-24 帝国制药美国公司 纳洛酮经皮给药装置及其使用方法
JP2023513781A (ja) * 2020-02-14 2023-04-03 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用ナロキソン組成物およびそれを使用するための方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837881A (en) * 1952-12-13 1958-06-10 Lawrence A Schneider Encapsulated product and method and apparatus for making same
US3249109A (en) * 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
US4629539A (en) * 1982-07-08 1986-12-16 Tdk Corporation Metal layer patterning method
EP0116538A4 (en) * 1982-08-25 1985-04-25 Joel E Bernstein METHOD FOR TREATING PRURITIS AND COMPOSITION THEREOF.
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
DE3545926A1 (de) * 1985-12-23 1987-07-02 Allan Gerhard Fruehauf Tuch oder dgl. mit darin integrierten, einen wirkstoff enthaltenden kapseln
EP0267617B1 (en) * 1986-11-14 1992-06-24 Theratech, Inc. Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols
ES2036670T3 (es) * 1987-03-09 1993-06-01 Alza Corporation Composicion para prevenir una alergia de contacto por administracion simultanea de un corticoesteroide con un farmaco sensibilizante.
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Also Published As

Publication number Publication date
NZ247173A (en) 1997-07-27
EP0429039B1 (en) 1995-03-08
DE69017596D1 (de) 1995-04-13
DK0429039T3 (da) 1995-03-27
CA2030237C (en) 1997-12-30
FI905718A0 (fi) 1990-11-20
EP0429039A2 (en) 1991-05-29
ATE119393T1 (de) 1995-03-15
EP0429039A3 (en) 1991-10-16
CA2030237A1 (en) 1991-05-21
US5096715A (en) 1992-03-17
DE69017596T2 (de) 1995-07-06
NZ236104A (en) 1993-04-28
FI905718A (fi) 1991-05-21
AU639042B2 (en) 1993-07-15
AU6665090A (en) 1991-05-23

Similar Documents

Publication Publication Date Title
ES2074513T3 (es) Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo.
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
ES2054818T3 (es) Dispositivo mejorado para el suministro transdermal de farmacos.
GB2316004A (en) Novel formulations for transdermal delivery of pergolide
CO5261517A1 (es) Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis
ITMI913170A1 (it) Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
GB1390772A (en) Oral narcotic composition
ATE69724T1 (de) Selbstklebende vorrichtung zur transdermalen verabreichung eines wirkstoffs.
ATE284206T1 (de) Transdermal verabreichtes dextromethorphan als hustenmittel
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
DE58906232D1 (de) Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe.
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
Klotz Long-term safety of Nefopam hydrochloride (Acupan), a new analgesic formulation.
ATE74523T1 (de) Praeparat zur intramuskulaeren injektion von medikamenten, vitaminen oder impfstoffen.
DE3770658D1 (de) Injizierbare arzneiformulierungen von substanzen mit allgemeiner anaesthetischer wirkung.
DE3786168D1 (de) Verwendung von para-aminobenzoesaeure zur herstellung eines arzneimittels zur bekaempfung von photoallergien.
SE8304818L (sv) Medicin med magsarslekande, spasmolytisk och lokalanesteserande verkan
RU2005101874A (ru) Синергетическое взаимодействие абакавира и аловудина
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
BR9808876A (pt) Sistema de liberação de medicamento
TH11673B (th) วัสดุทรามาคอล n-ออกไซด์ อีแนนชิโอเมอร์ และสารผสมของมันและที่ใช้

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 429039

Country of ref document: ES